CD274 and non-small cell lung carcinoma: The other 20% of NSCLC patients receive a diagnosis in the third stage of non-small cell lung cancer (NSCLC), which includes a comprehensive and heterogeneous category (IIIA-IIIB-IIIC), in prognostic and therapeutic terms, that can be managed with different strategies in a multidisciplinary approach, such as surgical treatment in selected cases followed by chemotherapy and radiotherapy, neoadjuvant chemotherapy with or without radiotherapy followed by surgical resection, or radical chemoradiotherapy followed by immunotherapy with durvalumab in patients with PD-L1 > 1% [15,16,17,18,19].